Jeffrey E. Teigler
Beth Israel Deaconess Medical Center
10 Papers
118 Citations
Jeffrey E. Teigler is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Immune system & Innate immune system. The author has an hindex of 9, co-authored 10 publications. Previous affiliations of Jeffrey E. Teigler include Ragon Institute of MGH, MIT and Harvard.
Chat about Author
Papers
The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys
Jeffrey E. Teigler,Sanjay Phogat,Genoveffa Franchini,Vanessa M. Hirsch,Nelson L. Michael,Dan H. Barouch,Dan H. Barouch +6 more
TL;DR: It is shown that the canarypox virus-based vector ALVAC induced distinct systemic proinflammatory and antiviral cytokine and chemokine levels following the vaccination of rhesus monkeys, suggesting that there are substantial biological differences among leading poxvirus vaccine vectors that may influence resultant adaptive immune responses following vaccination.
68
Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors
Peter Abbink,Lori F. Maxfield,David Ng’ang’a,Erica N. Borducchi,M. Justin Iampietro,Christine A. Bricault,Jeffrey E. Teigler,Stephen Blackmore,Lily Parenteau,Kshitij Wagh,Scott A. Handley,Guoyan Zhao,Herbert W. Virgin,Bette T. Korber,Dan H. Barouch,Dan H. Barouch +15 more
TL;DR: The primary isolation and vectorization of three novel adenoviruses from rhesus monkeys are described, representing a new class of candidate vaccine vectors that exhibit virologic and immunologic characteristics that make them attractive as potential vaccine vectors for both HIV-1 and other pathogens.
Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
Hualin Li,Elizabeth G. Rhee,Katherine Masek-Hammerman,Jeffrey E. Teigler,Peter Abbink,Dan H. Barouch +5 more
TL;DR: Receptor usage was assessed using CD46 transgenic mouse cells, as well as by CARand CD46-specific mAb blocking studies using human PBMC, to assess immunologic and inflammatory responses at mucosal surfaces.
Augmented Replicative Capacity of the Boosting Antigen Improves the Protective Efficacy of Heterologous Prime-Boost Vaccine Regimens
Pablo Penaloza-MacMaster,Jeffrey E. Teigler,Rebecca C. Obeng,Zi H. Kang,Nicholas M. Provine,Lily Parenteau,Stephen Blackmore,Joshua Ra,Erica N. Borducchi,Dan H. Barouch,Dan H. Barouch +10 more
TL;DR: It is suggested that the replicative capacity of the boosting antigen influences the protective efficacy afforded by prime-boost vaccine regimens and a benefit of robustly replicating vaccine vectors is suggested.
11